A dibromobenzyl derivative with a structure shown as formula I, a stereoisomer or a pharmaceutically acceptable salt thereof and a preparation method and an application of the dibromobenzyl derivative are provided. The dibromobenzyl derivative or the stereoisomer thereof is superior in in-vivo pharmacokinetic stability and drug efficacy, and capable of being used for preparing respiratory drugs, in particular the apophlegmatic drugs.

##STR00001##

Film products, especially suitable for oral delivery, which can be formed during manufacture in the form of large and/or heavy film strips or sheets and subsequently cut into uniform dosage units, each dosage unit being uniform in content and having distributed therein a linear polysaccharide, such as pullulan, a plasticizer, and an active component.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.

The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.

The present invention refers to a composition comprising eriodictyol and guaifenesin. In particular, the present invention refers to a composition comprising eriodictyol and guaifenesin, said composition being for medical use, in particular for use in the prevention and treatment of respiratory diseases. Moreover, the present invention relates to the use of eriodictyol and guaifenesin for the preparation of a pharmaceutical composition. Finally, the present invention relates to the use of eriodictyol for masking or inhibiting the bitter taste of guaifenesin or guaifenesin comprising compositions.

The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis.

Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system.

Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.

Provided are mucolytic agents represented by formula (Ia)-(Id): ##STR00001##
where the structural variables R.sub.1, R.sub.2, R.sub.5 and R.sub.6 are as defined herein. Also provided are a variety of methods of treatment which take advantage of the mucolytic properties of the compounds represented by formula (Ia)-(Id).

The present invention provides a micelle comprising an anionic micelle and a protecting agent surrounding the anionic micelle, the anionic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being anionized under basic conditions and has anionic micelle-forming ability, the protecting agent protecting the anionic micelle. The present invention also provides a micelle comprising a cationic micelle and a protecting agent surrounding the cationic micelle, the cationic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being cationized under acidic conditions and has cationic micelle-forming ability, the protecting agent protecting the cationic micelle.